LV10655B - Endogenous gene expression modification with regulatory element - Google Patents

Endogenous gene expression modification with regulatory element Download PDF

Info

Publication number
LV10655B
LV10655B LVP-93-27A LV930027A LV10655B LV 10655 B LV10655 B LV 10655B LV 930027 A LV930027 A LV 930027A LV 10655 B LV10655 B LV 10655B
Authority
LV
Latvia
Prior art keywords
gene
dna
cell line
segment
regulatory
Prior art date
Application number
LVP-93-27A
Other languages
English (en)
Latvian (lv)
Other versions
LV10655A (lv
Inventor
Scott C Chappel
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23806064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10655(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of LV10655A publication Critical patent/LV10655A/xx
Publication of LV10655B publication Critical patent/LV10655B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
LVP-93-27A 1989-12-22 1993-01-13 Endogenous gene expression modification with regulatory element LV10655B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45478389A 1989-12-22 1989-12-22
PCT/US1990/007642 WO1991009955A1 (fr) 1989-12-22 1990-12-21 Modification de l'expression de genes endogenes a l'aide d'un element regulateur

Publications (2)

Publication Number Publication Date
LV10655A LV10655A (lv) 1995-04-20
LV10655B true LV10655B (en) 1995-08-20

Family

ID=23806064

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-27A LV10655B (en) 1989-12-22 1993-01-13 Endogenous gene expression modification with regulatory element

Country Status (26)

Country Link
EP (5) EP0779362B2 (fr)
JP (3) JP3501286B2 (fr)
KR (1) KR0176693B1 (fr)
AR (1) AR245776A1 (fr)
AT (2) ATE264916T1 (fr)
AU (1) AU645294B2 (fr)
BG (1) BG60624B1 (fr)
BR (1) BR9007937A (fr)
CA (1) CA2071989C (fr)
DE (3) DE69031172T2 (fr)
DK (2) DK0505500T3 (fr)
ES (2) ES2104690T3 (fr)
FI (1) FI107391B (fr)
GR (1) GR3025057T3 (fr)
HK (2) HK1000547A1 (fr)
HU (1) HU217212B (fr)
IL (4) IL96765A0 (fr)
LT (1) LT3998B (fr)
LV (1) LV10655B (fr)
NO (1) NO311896B1 (fr)
OA (1) OA09594A (fr)
RO (1) RO109864B1 (fr)
RU (1) RU2128227C1 (fr)
UA (1) UA42675C2 (fr)
WO (1) WO1991009955A1 (fr)
ZA (1) ZA9010392B (fr)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
EP0747485B1 (fr) * 1989-11-06 1998-12-02 Cell Genesys, Inc. Production de protéines par recombinaison homologue
GB9008746D0 (en) * 1990-04-18 1990-06-13 Connaught Lab The use of autologous promoters to express gene products in bordetella
US5643753A (en) 1990-04-18 1997-07-01 Connaught Laboratories Limited Use of autologous promoters to express gene products in bordetella
EP0584214B1 (fr) * 1991-05-06 2004-07-28 Cell Genesys, Inc. Manipulation et expression de genes a l'aide d'elements de genome
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
AU4383293A (en) * 1992-05-19 1993-12-13 Tsi Corporation Production of transgenics by joining regulatory and coding regions in vivo
AU4401993A (en) * 1992-06-04 1993-12-30 Exemplar Corporation Insertion of heterologous dna outside of known chromosomal genes
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5733753A (en) * 1992-12-22 1998-03-31 Novo Nordisk A/S Amplification of genomic DNA by site specific integration of a selectable marker construct
DK153992D0 (da) * 1992-12-22 1992-12-22 Novo Nordisk As Metode
JP3654446B2 (ja) 1993-12-23 2005-06-02 メルク アンド カンパニー， インコーポレイテッド マウス細胞のための相同的組換え抗体発現系
AU738395B2 (en) * 1994-05-13 2001-09-20 Transkaryotic Therapies, Inc. DNA construct for effecting homologous recombination and uses thereof
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7148004B1 (en) 1997-01-16 2006-12-12 The Rockefeller University Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
US7084252B1 (en) 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
US7619079B2 (en) 1996-02-14 2009-11-17 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
DE69739497D1 (de) 1996-10-01 2009-08-27 Geron Corp Menschlische Telomerase katalytische Untereinheit
US5925544A (en) * 1996-11-18 1999-07-20 Novo Nordisk A/S Method of homologous recombination followed by in vivo selection of DNA amplification
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5888809A (en) * 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DE59813758D1 (de) * 1997-07-23 2006-11-16 Roche Diagnostics Gmbh Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US5932465A (en) * 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
JP2002504341A (ja) 1998-02-23 2002-02-12 アイコス コーポレイション ホスホジエステラーゼ１０
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6071691A (en) * 1998-04-27 2000-06-06 Oregon Health Science University Materials and methods for modulating differentiation
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
CN1307642A (zh) * 1998-05-27 2001-08-08 诺沃诺尔迪斯克生物技术有限公司 通过改变基因拷贝数制备多肽的方法
US6476211B1 (en) 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
JP2002520040A (ja) 1998-07-16 2002-07-09 ハイセック，インコーポレーテッド 新規ｃｄ３９様ポリペプチドに関する方法および材料
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
ATE445335T1 (de) 1998-12-23 2009-10-15 Sinai School Medicine Hemmstoffe zur unterdrückung des bitteren geschmacks
US6783959B1 (en) 1999-01-29 2004-08-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
JP2004501601A (ja) * 1999-02-19 2004-01-22 アサーシス，インコーポレイテッド 標的化によらない内在性遺伝子の活性化組成物および活性化方法
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
EP1192258A2 (fr) 1999-06-16 2002-04-03 Icos Corporation Materiaux poly(adp-ribose) polymerase 2 humains et procedes
US6632665B1 (en) 1999-08-09 2003-10-14 Wake Forest University Human gene encoding 3′-5′ exonuclease
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
JP2003512838A (ja) 1999-10-22 2003-04-08 ファルマシア・アンド・アップジョン・カンパニー ショウジョウバエｇタンパク質結合レセプター、核酸、およびそれに関連する方法。
US7314716B2 (en) 1999-11-19 2008-01-01 Mount Sinai School Of Medicine Gustducin γ subunit materials and methods
US6465620B1 (en) 2000-01-21 2002-10-15 Hyseq, Inc. Methods and materials relating to novel von Willebrand/Thrombospondin-like polypeptides and polynucleotides
US6586390B1 (en) 2000-01-21 2003-07-01 Hyseq, Inc. Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
EP1297112A2 (fr) 2000-05-22 2003-04-02 PHARMACIA & UPJOHN COMPANY Nouvelles metalloproteinases matricielles
PT2077279E (pt) 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
AU2001271839A1 (en) 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
US6787684B2 (en) 2000-10-16 2004-09-07 E. & J. Gallo Winery Lipoxygenase genes from Vitis vinifera
ATE505204T1 (de) 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
EP1407787B1 (fr) 2001-06-20 2009-04-29 Dainippon Sumitomo Pharma Co., Ltd. Procede facilitant le transfert d'acides nucleiques
EP2003451B1 (fr) 2001-06-26 2012-05-30 Senomyx, Inc. Récepteurs gustatifs umamis hétero-oligomères t1r1-t1r3, lignées cellulaires exprimant lesdits récepteurs et utilisation de ces récepteurs pour identifier des composés gustatifs umamis
CN1610830A (zh) 2001-07-10 2005-04-27 塞诺米克斯公司 特异性t2r味觉受体在鉴定阻断苦味觉的化合物中的应用
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
WO2003100007A2 (fr) 2002-05-24 2003-12-04 Schering-Plough Ltd. Gene eta-1 et procedes d'utilisation
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1572291B1 (fr) 2002-10-08 2013-04-03 Ares Trading S.A. Utilisation de cytokine pouvant se fixer a il-18bp et inhiber l'activite d'une seconde cytokine
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2802143C (fr) 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Polynucleotide codant un sparc comme agent sensibilisant de therapie du cancer
ES2625342T3 (es) 2003-06-27 2017-07-19 Monell Chemical Senses Center Receptores gustativos de la familia T1R del gato doméstico
RU2006106920A (ru) 2003-08-06 2007-09-20 Синомикс Инк. (Us) Гетеро-олигомерные вкусовые рецепторы t1r, клеточные линии, которые экспрессируют указанные рецепторы и вкусовые соединения
BRPI0414887A (pt) 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
EP1696034A4 (fr) * 2003-12-19 2006-12-27 Dainippon Sumitomo Pharma Co Methode de transfert d'acide nucleique
WO2005116069A2 (fr) 2004-04-14 2005-12-08 Monell Chemical Senses Center Recepteurs de gout de la famille t1r, provenant d'un chien domestique
ES2570665T3 (es) 2004-04-23 2016-05-19 Zoetis Services Llc Factor de permisividad celular para virus, y usos del mismo
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
EP1797183B1 (fr) 2004-09-02 2012-08-01 Yale University Regulation d'oncogenes par des micro-arn
US7785807B2 (en) 2004-12-13 2010-08-31 Monell Chemical Senses Center Voltage-gated, pH-sensitive anion channel and its novel splice variant involved in taste sensation
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
WO2006101629A2 (fr) 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated Variant d'epissage d'une sous-unite alpha de proteine type iii de canal sodique
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
US8354384B2 (en) 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
WO2007031566A1 (fr) 2005-09-14 2007-03-22 Ares Trading S.A. Méthode de dosage quantitatif des poloxamères
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
EP1937718B1 (fr) 2005-10-20 2017-12-06 Senomyx, Inc. Récepteurs gustatifs chimères humains des saveurs sucre-umami et umami-sucre
ES2434494T3 (es) 2005-12-08 2013-12-16 Amgen, Inc. Células huésped mejoradas y métodos de cultivo
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
WO2008141176A1 (fr) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Procédés de traitement des ulcères de la peau
KR101461659B1 (ko) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
WO2009010107A1 (fr) 2007-07-19 2009-01-22 Hannelore Ehrenreich Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques
US8420373B2 (en) 2007-07-27 2013-04-16 Universiteit Gent Permissive cells and uses thereof
US7939671B2 (en) 2007-08-21 2011-05-10 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
US20120264688A1 (en) 2009-09-23 2012-10-18 Walter Hinderer Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
EP2325194A1 (fr) 2009-11-24 2011-05-25 Glycotope GmbH Processus de purification de glycoprotéines
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US20120329092A1 (en) 2010-01-28 2012-12-27 Glycotope Gmbh Process for the purification of glycoproteins
EP2558497A2 (fr) 2010-04-15 2013-02-20 Amgen Inc. Protéines de liaison au récepteur de fgf humain et à beta-klotho
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
JP5735650B2 (ja) 2010-09-14 2015-06-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｅｇ化エリスロポエチンを精製するための方法
US8759313B2 (en) 2011-08-03 2014-06-24 The Charlotte-Mecklenburg Hospital Authority Treatment of fibrosis using microRNA 19b
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013009971A1 (fr) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Procédé de détection et de criblage et matériaux utiles dans l'exécution de celui-ci
IN2014MN00974A (fr) 2011-12-16 2015-04-24 Targetgene Biotechnologies Ltd
BR112016002622B1 (pt) 2013-08-20 2023-04-11 Lek Pharmaceuticals D.D Meio de cultura celular e uso de selênio
JP6841753B2 (ja) 2014-09-15 2021-03-10 ザ チルドレンズ メディカル センター コーポレーション ヒストンｈ３−リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物
CN109415427A (zh) 2016-07-15 2019-03-01 豪夫迈·罗氏有限公司 用于纯化聚乙二醇化的促红细胞生成素的方法
ES2905105T3 (es) 2017-12-29 2022-04-07 Hoffmann La Roche Procedimiento para proporcionar una composición de proteína PEGilada
SG11202005952TA (en) 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
US20200323993A1 (en) 2017-12-29 2020-10-15 Hoffmann-La Roche Inc. Process for providing pegylated protein composition
WO2022159414A1 (fr) 2021-01-22 2022-07-28 University Of Rochester Érythropoïétine pour un dysfonctionnement gastrointestinal
WO2024091824A1 (fr) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Différenciation et reprogrammation de chondrocyte

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE106892T1 (de) * 1985-04-08 1994-06-15 Amgen Inc Verfahren und hybridpromotor zur steuerung der exogenen gentranskription.
EP0273085A1 (fr) * 1986-12-29 1988-07-06 IntraCel Corporation Procédé pour faire entrer des acides nucléiques dans des cellules eucaryotes
ZA88319B (en) * 1987-02-06 1988-08-12 Lubrizol Enterprises, Inc. Ocs enhancer
GB8807683D0 (en) * 1988-03-31 1988-05-05 Ici Plc Regulation of gene expression
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991005052A1 (fr) * 1989-09-28 1991-04-18 Leningradsky Gosudarstvenny Universitet Procede d'obtention d'un polypeptide presentant une activite d'interleukine-2 humaine, secrete par des cellules de levure, saccharomyces cerevisiae
EP0747485B1 (fr) * 1989-11-06 1998-12-02 Cell Genesys, Inc. Production de protéines par recombinaison homologue
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production

Also Published As

Publication number Publication date
NO922436L (no) 1992-06-19
JP3740134B2 (ja) 2006-02-01
EP0779362B1 (fr) 2004-04-21
OA09594A (en) 1993-04-30
JP3501286B2 (ja) 2004-03-02
DE779362T1 (de) 2001-04-05
DE69034135T2 (de) 2004-08-26
FI922863A0 (fi) 1992-06-18
EP0779362B2 (fr) 2012-06-13
DE69031172T2 (de) 1998-03-12
FI107391B (fi) 2001-07-31
LV10655A (lv) 1995-04-20
EP1375666A2 (fr) 2004-01-02
HU9202068D0 (en) 1992-10-28
HK1000547A1 (en) 1998-04-03
LT3998B (en) 1996-06-25
JPH05504682A (ja) 1993-07-22
CA2071989A1 (fr) 1991-06-23
BR9007937A (pt) 1992-11-17
RU2128227C1 (ru) 1999-03-27
DE69031172D1 (de) 1997-09-04
EP1482053A3 (fr) 2007-10-17
HK1000786A1 (en) 2005-01-14
IL116046A0 (en) 1996-01-31
DE69034135T3 (de) 2012-08-23
WO1991009955A1 (fr) 1991-07-11
AR245776A1 (es) 1994-02-28
RO109864B1 (ro) 1995-06-30
EP0505500B1 (fr) 1997-07-30
FI922863A (fi) 1992-06-18
IL164252A0 (en) 2005-12-18
CA2071989C (fr) 1999-07-27
EP1484412A2 (fr) 2004-12-08
EP0505500A1 (fr) 1992-09-30
ES2151463T1 (es) 2001-01-01
GR3025057T3 (en) 1998-01-30
KR0176693B1 (ko) 1999-04-01
DK0779362T4 (da) 2012-07-30
ATE264916T1 (de) 2004-05-15
HUT62657A (en) 1993-05-28
EP1375666A3 (fr) 2007-09-26
EP0779362A1 (fr) 1997-06-18
JP2004000233A (ja) 2004-01-08
DK0505500T3 (da) 1997-08-25
BG60624B1 (bg) 1995-10-31
ES2104690T3 (es) 1997-10-16
IL96765A0 (en) 1991-09-16
NO922436D0 (no) 1992-06-19
ES2151463T3 (es) 2004-10-01
DE69034135D1 (de) 2004-05-27
IL116046A (en) 2007-03-08
ZA9010392B (en) 1992-01-29
LTIP1595A (en) 1995-07-25
HU217212B (hu) 1999-12-28
EP1482053A2 (fr) 2004-12-01
ATE156189T1 (de) 1997-08-15
JP2004089200A (ja) 2004-03-25
DK0779362T3 (da) 2004-05-10
UA42675C2 (uk) 2001-11-15
AU7183691A (en) 1991-07-24
NO311896B1 (no) 2002-02-11
ES2151463T5 (es) 2012-10-29
AU645294B2 (en) 1994-01-13
EP1484412A3 (fr) 2007-10-17

Similar Documents

Publication Publication Date Title
EP0505500B1 (fr) Modification de l'expression de genes endogenes a l'aide d'un element regulateur par recombinaison homologue
US5272071A (en) Method for the modification of the expression characteristics of an endogenous gene of a given cell line
Kaufman et al. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus
Elroy-Stein et al. Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells.
RU2233334C2 (ru) Способ встраивания нужной днк в геном клетки млекопитающего и векторная система для его осуществления
EA010863B1 (ru) Отбор клеток-хозяев, экспрессирующих белок на высоких уровнях
WO1997016533A1 (fr) Chromosomes mammaliens artificiels et procedes d'utilisation desdits chromosomes
JPH04505104A (ja) 相同組換え法を用いてのタンパク質の生成
EP0832273A1 (fr) Chromosome synthetique de mammifere et procedes de construction de celui-ci
WO2002057447A2 (fr) Methodes et reactifs pour amplification et manipulation de sequences vecteurs et cibles d'acide nucleique
EP0585983A2 (fr) Vecteur nucléotidique comportant au gène de facteur inhibant la traduction, un IRES et un gène d'intérêt
Lee et al. High‐efficiency protein expression mediated by enterovirus 71 internal ribosome entry site
US20230159958A1 (en) Methods for targeted integration
JP2651316B2 (ja) 相同組換え細胞選別法
KR20050084867A (ko) 페리틴 중쇄 유전자 로커스에 기초한 고발현 로커스 벡터